The global osteoarthritis market revenues are forecasted to touch US$10.92 billion in 2025, growing at a CAGR of 9.85% for the period spanning from 2021 to 2025.
Factors such as increasing occurrence of osteoarthritis, growing geriatric population, rising healthcare expenditure per capita, growing obese population and improving consumer confidence index are expected to drive the market growth. However, growth of the industry would be challenged by associated business risk, patient health-associated risk and stringent regulations. A few notable trends include growth in pharmaceutical R&D expenditures, progressing product pipeline, advancement in osteoarthritis treatments and growth in online pharmaceutical sales.
In 2020, the outbreak of COVID-19 pandemic has created an unfavorable impact on the market as the osteoarthritis therapeutics sales declined during Q1-2020.
The global osteoarthritis market by treatment type is segmented into categories i.e. IA Injections (corticosteroids and HA) and Drugs (NSAIDs & Analgesics). Among them, IA injections held the largest share of the industry revenues due to growth in prevalence of joint disorders across the world.
The fastest growing regional market is North America. The growth was supported by growth in geriatric population, surge in HA injections demand, rise in sports injuries and development in e-commerce industry. The U.S. is the largest market and is already well-penetrated at developed market levels
Scope of the report:
The report provides a comprehensive analysis of the global osteoarthritis market, segmented into IA Injections and Drugs (Analgesics and NSAIDs).
The major regional markets (North America, Europe and Asia-Pacific) have been analysed along with country coverage of US.
The market dynamics such as growth drivers, market trends and challenges are analysed in-depth.
The competitive landscape of the market, along with the company profiles of leading players i.e. Johnson & Johnson, Novartis AG, Bayer AG, GlaxoSmithKline Plc, Pfizer Inc. and Sanofi S.A. are also presented in detail.
Key Target Audience:
Osteoarthritis Therapeutics Manufacturers
Ingredient Suppliers
End Users
Consulting Firms
Investment Banks
Government Bodies & Regulating Authorities
